152 related articles for article (PubMed ID: 37300262)
21. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Fischer LE; Stintzing S; von Weikersthal LF; Modest DP; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Giessen-Jung C; Uhlig J; Peuser B; Denzlinger C; Stahler A; Weiss L; Heinrich K; Held S; Jung A; Kirchner T; Heinemann V
Br J Cancer; 2022 Sep; 127(5):836-843. PubMed ID: 35637412
[TBL] [Abstract][Full Text] [Related]
23. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
[TBL] [Abstract][Full Text] [Related]
24. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.
Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661
[TBL] [Abstract][Full Text] [Related]
25. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
[TBL] [Abstract][Full Text] [Related]
26. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
Benavides M; Gómez-España A; García-Alfonso P; González CG; Viéitez JM; Rivera F; Safont MJ; Abad A; Sastre J; Valladares-Ayerbes M; Carrato A; González-Flores E; Robles L; Salud A; Alonso-Orduña V; Montagut C; Asensio E; Díaz-Rubio E; Aranda E;
Eur J Surg Oncol; 2022 May; 48(5):1123-1132. PubMed ID: 34872775
[TBL] [Abstract][Full Text] [Related]
27. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Ann Oncol; 2017 Aug; 28(8):1862-1868. PubMed ID: 28449055
[TBL] [Abstract][Full Text] [Related]
28. Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread.
Hsu HC; Huang KC; Chen WS; Jiang JK; Yang SH; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Yang TS; Chen CC; Chao Y; Teng HW
Sci Rep; 2021 Jul; 11(1):15370. PubMed ID: 34321583
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study.
Goktas Aydin S; Kavak EE; Topcu A; Bayramgil A; Akgul F; Kahraman S; Aykan MB; Altıntas YE; Helvaci K; Urun Y; Bilici A; Seker M; Sendur MAN; Olmez OF; Acikgoz O; Cicin I
Biomol Biomed; 2023 Nov; 23(6):1089-1095. PubMed ID: 37289436
[TBL] [Abstract][Full Text] [Related]
30. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Circulating DNA to Assess Prognoses for Metastatic Colorectal Cancer Patients Treated with Regorafenib Dose-Escalation Therapy: A Retrospective, Exploratory Analysis of the RECC Trial.
Ohta R; Yamada T; Nakamura M; Enomoto M; Takahashi M; Yokomizo H; Kosugi C; Ishimaru K; Sonoda H; Kuramochi H; Yoshida Y; Furuya S; Hirata K; Yoshida H; Nozawa K; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
Digestion; 2023; 104(3):233-242. PubMed ID: 36646047
[TBL] [Abstract][Full Text] [Related]
32. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry.
Alawawdeh A; Price T; Karapetis C; Piantadosi C; Padbury R; Roy A; Maddern G; Moore J; Carruthers S; Roder D; Townsend AR
Asia Pac J Clin Oncol; 2022 Aug; 18(4):428-433. PubMed ID: 34811937
[TBL] [Abstract][Full Text] [Related]
34. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
35. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
[TBL] [Abstract][Full Text] [Related]
36. Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
Vitale P; Zanaletti N; Famiglietti V; De Falco V; Cervantes A; Rosellò S; Fenocchio E; Milanesio M; Lombardi P; Ciardiello D; Martini G; Martinelli E; Ciardiello F; Troiani T; Napolitano S
Clin Colorectal Cancer; 2021 Sep; 20(3):227-235. PubMed ID: 34226142
[TBL] [Abstract][Full Text] [Related]
37. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
38. Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting.
Unseld M; Filip M; Seirl S; Gleiss A; Bianconi D; Kieler M; Demyanets S; Scheithauer W; Zielinski C; Prager G
Neoplasma; 2018; 65(4):599-603. PubMed ID: 29940763
[TBL] [Abstract][Full Text] [Related]
39. The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study.
Sahin S; Karatas F
J BUON; 2019; 24(2):479-487. PubMed ID: 31127994
[TBL] [Abstract][Full Text] [Related]
40. The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib.
Yekedüz E; Aktaş EG; Köksoy EB; Doğan N; Ürün Y; Utkan G
Future Oncol; 2022 Mar; 18(9):1067-1076. PubMed ID: 35109668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
